Gilead Sciences, Inc. (NASDAQ:GILD) has made a significant investment in Assembly Biosciences, Inc. (NASDAQ:ASMB), a company with a market capitalization of $94 million, by purchasing 940,499 shares of common stock. According to InvestingPro data, Assembly maintains a "GREAT" financial health score of 3.1 out of 5. The transaction, dated December 19, 2024, was executed at a price of $21.37 per share, totaling approximately $20.1 million. Following this acquisition, Gilead now holds 2,209,471 shares in Assembly Biosciences. This move underscores Gilead's interest in Assembly's pharmaceutical preparations sector. Assembly's stock has shown strong momentum with a 52% YTD return, and analysts maintain a "Buy" consensus with price targets suggesting potential upside. InvestingPro subscribers can access 8 additional key insights about Assembly's growth prospects and valuation metrics.
In other recent news, Assembly Biosciences has made significant strides in its collaboration with Gilead Sciences. The companies have amended their agreement, with Assembly Biosciences receiving an immediate payment of $10 million from Gilead for their joint drug development project, ABI-6250. Furthermore, Gilead has purchased additional equity in Assembly Biosciences, acquiring 940,499 shares of common stock.
In terms of product development, Assembly Biosciences reported positive interim results from the Phase 1a study of its recurrent genital herpes drug candidate, ABI-5366, and has started screening participants for the Phase 1b study. The company has also initiated an at-the-market equity program with Jefferies LLC, providing a flexible mechanism for capital raising.
Analysts' perspectives on these developments vary. H.C. Wainwright maintained a neutral stance on Assembly Biosciences, while Mizuho (NYSE:MFG) Securities reiterated an Outperform rating, emphasizing the drug's long-acting profile. Jefferies upgraded its rating from Hold to Buy, reflecting a positive outlook on the company's upcoming clinical data. These are recent developments that investors may want to monitor closely.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.